Deal overview
Sino Biopharmaceutical (HK:1177) reported a pair of commercial agreements that extend its partnerships with global drugmakers and prompted a notable jump in its Hong Kong-listed shares. The company said on Wednesday that a subsidiary, Chia Tai Tianqing Pharmaceutical Group, has granted AstraZeneca (ST:AZN) exclusive rights to develop, manufacture and commercialise an inhaled PDE3/4 inhibitor, TQC3721, outside China.
Financial terms
Under the arrangement, Sino Biopharm will receive an upfront payment of $200 million. The agreement also provides for potential additional payments of up to $1.9 billion linked to development, regulatory and sales milestones, and includes tiered double-digit royalties on annual net sales.
Expanded collaboration with GSK
Separately, Sino Biopharmaceutical disclosed it has broadened its strategic commercial collaboration with GSK plc (LON:GSK). The expanded arrangement gives Sino Biopharm commercialisation rights in mainland China for two GSK respiratory medicines, Trelegy Ellipta and Anoro Ellipta. Under the terms stated by the company, Sino Biopharm will manage importation, distribution, hospital access and promotional activities for those products, and will recognise revenue from Chinese sales on its own books.
Market response
The announcements were accompanied by immediate stock market movement. Shares of Sino Biopharm climbed as much as 7% to HK$5.15 by 06:04 GMT before trimming some of the advance.
Context within company strategy
The deals further Sino Biopharm’s recent drive to partner with multinational pharmaceutical firms and to monetise its research pipeline through cross-border licensing and commercial agreements. Earlier in the year, the company licensed selected rights to TQC3721 to Sanofi, and in May it entered a strategic collaboration with GSK to support the launch of hepatitis B therapy bepirovirsen in China. Sino Biopharm said it has been steadily expanding such licensing and commercial partnerships over the past two to three years.
Implications for stakeholders
For Sino Biopharm, the AstraZeneca licence provides near-term cash and potential long-term upside tied to milestones and royalties, while the expanded GSK deal assigns the company a direct role in bringing two established respiratory products to Chinese healthcare channels. For AstraZeneca and GSK, the agreements secure rights or local commercial execution for therapies outside or inside China respectively, as structured between the parties.